Vivoryon Therapeutics NV at Virtual R&D Event with Key Opinion Leaders Transcript
(technical difficulty)
Discussion on the design and rationale of the VIVIAD Phase 2b study of our lead program, varoglutamstat in Alzheimer's disease. We are very pleased to be joined by our moderator of today's event, Dr. Philip Scheltens, in addition to guest speakers, Dr. Stephan Schilling, Dr. John Harrison, Dr. Sietske Sikkes and Dr. Willem de Haan. Following the moderated discussion and brief presentations, we will host a Q&A session. As a reminder, you are welcome to submit questions in advance via the webcast portal. You can find the respective tab in the upper right corner of the webcast player.
Next slide, please. Before we start, I would like to remind you that during this conference call, we will present and discuss certain forward-looking statements concerning the development of Vivoryon's core technologies, the progress of its current research and development programs and the initiation of additional programs. Should actual results differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
